Tucaxen 150 mg Tablet is an oral targeted anticancer medicine containing Tucatinib, a highly selective tyrosine kinase inhibitor. It is primarily used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, particularly in patients with advanced or metastatic disease. Tucaxen 150 mg is designed to specifically inhibit HER2 signaling while minimizing inhibition of epidermal growth factor receptor (EGFR), helping to improve efficacy and tolerability in long-term cancer management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted Cancer Therapy
Tyrosine Kinase Inhibitor

Indications

Tucaxen 150 mg is indicated for the treatment of adult patients with HER2-positive advanced or metastatic breast cancer, including patients with brain metastases. It is used in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based treatment regimens in the metastatic setting.

Pharmacology and Mechanism of Action

Tucaxen 150 mg contains Tucatinib, an orally bioavailable, small-molecule tyrosine kinase inhibitor that selectively targets the intracellular kinase domain of HER2. Unlike less selective HER2 inhibitors, Tucatinib demonstrates minimal inhibition of EGFR, which reduces EGFR-related adverse effects such as severe skin rash and diarrhea.
By blocking HER2-mediated phosphorylation and downstream signaling pathways, including MAPK and PI3K/AKT, Tucaxen 150 mg inhibits tumor cell proliferation and promotes apoptosis in HER2-overexpressing cancer cells. Its high selectivity also contributes to central nervous system activity, making it effective in patients with HER2-positive breast cancer and brain metastases.

Dosage and Administration

• The recommended dose of Tucaxen is 150 mg taken orally twice daily, in combination with trastuzumab and capecitabine, or as directed by the physician.

• Tablets should be swallowed whole and may be taken with or without food.

• Treatment should continue until disease progression or unacceptable toxicity occurs.

• Dose modifications may be required based on tolerability, hepatic function, or drug interactions.

Drug Interactions

• Strong CYP3A4 inhibitors may increase Tucatinib plasma concentrations and require dose adjustments.

• Strong CYP3A4 inducers may reduce therapeutic effectiveness and should be avoided if possible.

• Concomitant use with drugs that affect hepatic enzymes should be closely monitored.

Side Effects

Common adverse effects associated with Tucaxen 150 mg include:

• Diarrhea

• Nausea and vomiting

• Fatigue

• Hand-foot syndrome

• Elevated liver enzymes

Liver function tests should be monitored regularly during treatment.

Pregnancy, Lactation, and Fertility

• Pregnancy: Tucaxen 150 mg may cause fetal harm and is not recommended during pregnancy. Effective contraception should be used during treatment.

• Lactation: Breastfeeding should be discontinued during therapy and for a period after the final dose.

• Fertility: No adequate data are available on the effects on human fertility.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Conditions

Store Tucaxen 150 mg at room temperature below 30°C. Protect from light and moisture. Keep out of reach of children and dispose of unused tablets properly.